Electrochemotherapy and electroporation-based treatments have been investigated across a range of solid tumour types, anatomical regions and treatment settings. The 2674 publications in the corpus are divided into 21 application areas. Evidence strength and clinical maturity differ markedly between indications; this page groups the areas by that maturity.
The two bars measure different things. The left one is the group's literature volume, the right one what proportion of that literature is clinical. Groups are ordered by volume, so the left column shortens from top to bottom; the right column not following it is the finding itself. “Clinical” covers randomized, prospective and retrospective studies, case series and reports, plus systematic reviews and guidelines.
| Tissue group | Areas | Literature volume | Clinical share | Evidence maturity |
|---|---|---|---|---|
| Basic ScienceGeneral Principles & Biophysics Devices & Clinical Trials | 2 | 782 | 15%118 | 1 Clinical Evidence 1 Exploratory Evidence |
| Deep Organ TumoursLiver Tumours Pancreatic Cancer Breast Cancer Colorectal Cancer Cholangiocarcinoma Lung & Peribronchial Tumours | 6 | 751 | 49%366 | 3 Clinical Evidence 2 Early Clinical Evidence 1 Preclinical Evidence |
| Skin & Superficial TumoursSkin & Cutaneous Tumours Malignant Melanoma Kaposi Sarcoma | 3 | 475 | 58%275 | 2 Clinical Evidence 1 Early Clinical Evidence |
| Special IndicationsVeterinary Oncology Vascular Malformations Electrochemotherapy in Metastatic Disease | 3 | 178 | 37%66 | 1 Clinical Evidence 2 Early Clinical Evidence |
| Urogynaecological TumoursProstate & Urological Tumours Vulvar Cancer Ovarian Tumours Endometrial Cancer | 4 | 169 | 57%96 | 2 Clinical Evidence 1 Preclinical Evidence 1 Exploratory Evidence |
| Musculoskeletal & CNSBone & Soft Tissue Sarcomas Brain Tumours | 2 | 100 | 33%33 | 1 Clinical Evidence 1 Preclinical Evidence |
| Head, Neck & OrbitHead & Neck Tumours | 1 | 74 | 73%54 | 1 Clinical Evidence |
Areas at clinical evidence level, ordered by clinical publication count. The figure on the right gives the strongest tier within that volume: the number of randomized trials, systematic reviews and guidelines. The order reflects publication volume, not therapeutic superiority.
Areas are grouped by evidence maturity by default. Switch the view to group them by tissue group instead.
At least 15 clinical publications plus a randomized trial, systematic review or guideline
This is the most mature indication group for electrochemotherapy.
Reported outcome domains
Safety and tolerability72Complete response60Objective response45Symptom control and palliation38
In locally advanced pancreatic cancer, encasement of the coeliac and mesenteric vessels blocks surgery and thermal ablation.
Reported outcome domains
Survival82Safety and tolerability38Local recurrence23Symptom control and palliation21
The liver is an organ where both electroporation regimes are used.
Reported outcome domains
Survival33Safety and tolerability33Local recurrence26Local tumour control14
The biophysics of electroporation, the cellular and tissue effects of pulse parameters, drug transport mechanisms and treatment planning are gathered in this area.
Reported outcome domains
Safety and tolerability34Objective response12Local recurrence12Complete response9
Cutaneous and subcutaneous melanoma metastases are the single tumour type most intensively studied with electrochemotherapy.
Reported outcome domains
Safety and tolerability34Objective response27Complete response26Symptom control and palliation20
The search for focal therapy in the prostate is shaped by the aim of preserving urinary and sexual function.
Reported outcome domains
Safety and tolerability34Cosmetic and functional outcome21Quality of life19Local recurrence13
Tumours in the head and neck lie close to critical anatomical structures, and in recurrent disease the surgical and radiotherapy options are often exhausted.
Reported outcome domains
Objective response23Safety and tolerability21Symptom control and palliation16Complete response15
Chest wall recurrences and skin metastases of breast cancer are among the established uses of electrochemotherapy.
Reported outcome domains
Safety and tolerability18Objective response15Complete response15Symptom control and palliation14
In bone metastases and soft tissue sarcomas, electrochemotherapy has been studied for pain palliation, local control and preoperative volume reduction.
Reported outcome domains
Quality of life9Safety and tolerability9Objective response8Local tumour control8
Vascular malformations are the only non-oncological application area.
Reported outcome domains
Safety and tolerability12Cosmetic and functional outcome5Quality of life3Local recurrence2
In vulvar cancer, electrochemotherapy is considered an organ-preserving option where surgical morbidity is high and in recurrent disease.
Reported outcome domains
Symptom control and palliation16Objective response12Quality of life9Safety and tolerability8
At least four clinical publications; no randomized evidence or guideline consensus yet
Electrochemotherapy has long been applied clinically in veterinary oncology, on spontaneously arising tumours in client-owned animals.
Reported outcome domains
Complete response10Safety and tolerability8Local tumour control6Objective response4
The skin lesions of Kaposi sarcoma are numerous and scattered; being able to treat many nodules in a single session makes electrochemotherapy practical in this…
Reported outcome domains
Complete response12Safety and tolerability7Objective response5Local tumour control4
In colorectal tumours electroporation has been studied in distinct contexts: liver metastases, local recurrence and endoscopically accessible lesions.
Reported outcome domains
Complete response6Safety and tolerability6Objective response3Local tumour control3
Treatment options in biliary tract tumours are limited and preserving the bile duct is critical.
Reported outcome domains
Safety and tolerability6Survival5Symptom control and palliation5Local recurrence3
The role of electrochemotherapy in metastatic disease concerns how the contribution of a local method to systemic disease should be defined.
Reported outcome domains
Safety and tolerability5Symptom control and palliation4Objective response3Complete response3
The weight lies in animal, in vitro and modelling studies; clinical series are limited
In the central nervous system, electroporation is investigated both for tumour ablation and for increasing drug passage by transiently opening the blood-brain…
Reported outcome domains
Complete response2Local tumour control1Safety and tolerability1
Lung and peribronchial sites are technically demanding because of the electrical conductivity of air-filled tissue and respiratory motion.
Reported outcome domains
Objective response1Survival1Symptom control and palliation1Safety and tolerability1
Electroporation in ovarian tumours has been studied largely through peritoneal spread and preclinical models; the number of clinical series is limited.
Reported outcome domains
No outcome domain detected
Publication counts fall below both thresholds; the area is still exploratory
Device documentation and clinical trial records are gathered under this heading.
Reported outcome domains
No outcome domain detected
Electroporation-based approaches in endometrial cancer are represented by only a handful of records in the corpus; the area is exploratory.
Reported outcome domains
Local recurrence1Symptom control and palliation1
Every publication is assigned to a single application area derived from the source folder structure and its citation fields. Areas are gathered into seven tissue groups by shared anatomical region or clinical context.
Evidence maturity is computed from the study-type distribution of the area's publications using automatic thresholds; it is not a formal GRADE assessment and cannot be used for treatment decisions. The clinical count covers randomized, prospective and retrospective studies, case series and reports, plus systematic reviews and guidelines.
“Reported outcome domains” are an automatic match of outcome terms appearing in the titles and abstracts of the area's clinical publications. The figure is the number of publications containing the term; it is not a measure of efficacy, a response rate or an indicator of success. Listing an outcome domain does not imply that the outcome was favourable.
The portal is intended for scientific and educational information only. Indication, device approval and drug licensing vary between countries.
Electroporation-based but not tumour therapy, and therefore excluded from the indication landscape, the anatomical explorer and the evidence maturity tables above. Kept in the corpus as context.
Cardiac Pulsed-Field Ablation135 publications
Non-Oncological IRE Applications10 publications
To see how the evidence behind an indication distributes by study type: Evidence Map →
